Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 35,660,000 shares, a growth of 8.7% from the June 30th total of 32,820,000 shares. Based on an average daily volume of 2,430,000 shares, the days-to-cover ratio is currently 14.7 days.
Analyst Upgrades and Downgrades
Several research firms have issued reports on HRTX. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of Heron Therapeutics in a research note on Thursday, May 16th. Rodman & Renshaw began coverage on shares of Heron Therapeutics in a research report on Thursday, June 13th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Capital One Financial initiated coverage on Heron Therapeutics in a report on Tuesday, April 23rd. They issued an “overweight” rating and a $6.00 price target for the company.
Read Our Latest Research Report on Heron Therapeutics
Institutional Investors Weigh In On Heron Therapeutics
Heron Therapeutics Stock Down 2.4 %
HRTX traded down $0.07 during midday trading on Tuesday, hitting $2.86. The company’s stock had a trading volume of 556,957 shares, compared to its average volume of 2,580,918. Heron Therapeutics has a 52-week low of $0.50 and a 52-week high of $3.93. The firm has a 50-day moving average price of $3.33 and a two-hundred day moving average price of $2.90.
Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.06. The company had revenue of $34.67 million for the quarter, compared to analysts’ expectations of $32.50 million. On average, research analysts expect that Heron Therapeutics will post -0.1 earnings per share for the current year.
About Heron Therapeutics
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Recommended Stories
- Five stocks we like better than Heron Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Conference Calls and Individual Investors
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- How to Invest in Small Cap StocksĀ
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.